Spero Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SPRO Nasdaq 2836 sperotherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Spero Therapeutics, Inc.

3 Promising Penny Stocks With Market Caps Up To $300M - Jan 7th, 2026 11:05 am
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis - Dec 19th, 2025 6:00 am
Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans? - Dec 15th, 2025 3:20 am
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Nov 28th, 2025 6:00 am
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update - Nov 13th, 2025 2:05 pm
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025 - Nov 4th, 2025 2:05 pm
3 Promising Penny Stocks With Market Caps Over $20M - Nov 4th, 2025 11:05 am
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs) - Oct 21st, 2025 12:00 am
Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek - Oct 14th, 2025 6:00 am
Best Momentum Stock to Buy for October 10th - Oct 10th, 2025 8:00 am
October 2025's Promising Penny Stocks To Consider - Oct 6th, 2025 12:05 pm
Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer - Sep 4th, 2025 5:00 am
ATA Creativity Global And Two Other Promising Penny Stocks - Sep 1st, 2025 12:04 pm
Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround - Aug 19th, 2025 7:35 am
Spero Therapeutics Inc (SPRO) Q2 2025 Earnings Call Highlights: Tepipenem HBR Trial Success and ... - Aug 13th, 2025 1:11 am
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update - Aug 12th, 2025 2:01 pm
Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025 - Aug 5th, 2025 2:05 pm
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer - Jul 4th, 2025 6:35 am
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek - Jul 2nd, 2025 6:34 am
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance - Jul 1st, 2025 9:55 am